इसराइल - हिब्रू - Ministry of Health

abbott medical laboratories ltd - ascorbic acid 35.3 mg / 100 ml; biotin 56.3 mcg / 100 ml - liquid - fat/carbohydrates/proteins/minerals/vitamins, combinations - high calorie, complete balanced nutrion, for liquid diets or supplementation.

इसराइल - हिब्रू - Ministry of Health

abbott medical laboratories ltd - ascorbic acid 65 mg / 100 ml; biotin 57.6 mcg / 100 ml - liquid - fat/carbohydrates/proteins/minerals/vitamins, combinations - ready to use, high - nitrogen isotonic liquid nutrition.

इसराइल - हिब्रू - Ministry of Health

abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

इसराइल - हिब्रू - Ministry of Health

abbott medical laboratories ltd - niacin 750 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

इसराइल - हिब्रू - Ministry of Health

abbott medical laboratories ltd - niacin 1000 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

इसराइल - हिब्रू - Ministry of Health

abbott medical laboratories ltd, israel - a/cambodia/e0826360/2020 (h3n2)-like strain; a/victoria/2570/2019 (h1n1)pdm09-like strain; b/washington/02/2019 (b/victoria lineage)-like virus - תרחיף להזרקה - b/washington/02/2019 (b/victoria lineage)-like virus 15 mcg/dose / 0.5 ml; a/cambodia/e0826360/2020 (h3n2)-like strain 15 mcg / 0.5 ml; a/victoria/2570/2019 (h1n1)pdm09-like strain 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, inactivated, whole virus - influenza virus vaccine.

इसराइल - हिब्रू - Ministry of Health

אבוט מעבדות רפואיות בע"מ באמצעות פרומדיקו בע"מ - אחות - enteral tube feeding is a method of providing nutrition to patients whose nutrition needs cannot be met by oral intake alone, for variety of clinical reasons. enteral feeding may be indicated for patients: who have difficulty chewing or swallowing, e.g. sroke, post-operative patients; with loss appetite due to chronic illness, e.g. cancer, hiv; with increased nutritional needs, e.g. wound healing, trauma/injury; with gastrointestinal disease, e.g. cancers of gi tract.

इसराइल - हिब्रू - Ministry of Health

abbott medical laboratories ltd, israel - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen

इसराइल - हिब्रू - Ministry of Health

abbott medical laboratories ltd, israel - propafenone hydrochloride - טבליות מצופות פילם - propafenone hydrochloride 150 mg - antiarrhythmics, class ic - prophylaxis and treatment of ventricular arrhythmias. prophylaxis and treatment of atrial fibrillation and flutter. prophylaxis and treatment of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms.

इसराइल - हिब्रू - Ministry of Health

abbott medical laboratories ltd, israel - propafenone hydrochloride - טבליות מצופות פילם - propafenone hydrochloride 300 mg - antiarrhythmics, class ic - prophylaxis and treatment of ventricular arrhythmias. prophylaxis and treatment of atrial fibrillation and flutter. prophylaxis and treatment of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms.